Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Work
Year: 2015
Type: article
Source: The Lancet
Institutions Smilow Cancer Hospital, Yale Cancer Center, Academic Medical Center, The Netherlands Cancer Institute, Seoul National University Hospital +16 more
Cites: 33
Cited by: 6,012
Related to: 10
FWCI: 255.2
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed